• Non ci sono risultati.

Scarica il programma in formato PDF

N/A
N/A
Protected

Academic year: 2022

Condividi "Scarica il programma in formato PDF"

Copied!
2
0
0

Testo completo

(1)

NON-SMALL CELL LUNG CANCER:

FOCUS ON OLIGOMETASTATIC DISEASE AND 2017 UPDATE

SCIENTIFIC COMMITTEE

SUPPORTED BY AN INDEPENDENT EDUCATIONAL SPONSORSHIP FROM Pier Franco Conte

Federico Rea

Aula Nievo, Palazzo del Bo, University of Padova

Via 8 Febbraio, 2 - 35122 Padova LOCATION

CME

ORGANIZING SECRETARIAT

via Pagliari, 4 - 26100 Cremona tel 0372 23310 fax 0372 569605 [email protected] www.overgroup.eu

March 31 - April 01, 2017

PADOVA

THORACIC ONCOLOGY PADOVA

Non-small cell lung cancer is one of the most frequent and dismal solid tumors. In the latest period it has become also one of the front runners in translational research and in the development of new

therapeutic strategies.

The increasing knowledge of biological heterogeneity of the disease and the new complexity in treatment approach lead to improved clinical outcome but also to the necessity of continuous research advances’

update.

One essential point in providing optimal care to lung cancer patients is the possibility to discuss and share the diagnostic and therapeutic program in a multidisciplinary team including

oncologists, surgeons, radiotherapists, pulmonologist, pathologists, radiologists.

The aim of the conference is to provide update on clinical cancer research in lung cancer and discuss specific topic in a

multidisciplinary group, through lectures, clinical cases discussion and opportunity to share opinions and experiences between speakers and attendees.

The TOP conference in 2017 will focus on the management of oligometastatic Non-small cell lung cancer (NSCLC).

The improvement of both surgical and non surgical local treatments, the definition of molecularly defined subgroups of NSCLC in which we can plan long-term control of metastatic disease and the new

perspectives of immunotherapy are elements that make the management of oligometastatic and oligoprogressing NSCLC one crucial point to improve clinical outcome of NSCLC patients.

In this specific topic, sharing and

discussing multidisciplinary experience is essential and may improve our clinical approach.

THORACIC ONCOLOGY PADOVA

WITH THE PATRONAGE OF

THE PATRONAGE HAS BEEN REQUESTED TO REGIONE DEL VENETO

COMUNE DI PADOVA DISCOG

Certificate awarding 7,7 CME credits will be e-mailed within 90 days after the end of the congress. The following medical sciences have been accredited for this Congress: Oncologists, surgeons, pathologists, biologists, medical genetics, medical genetics lab.,radiation therapists, radiodiagnostic therapists, neuro radiology, pharmacists, Occupational health, orthopedics, respiratory system disease.

(2)

NON-SMALL CELL LUNG CANCER:

FOCUS ON OLIGOMETASTATIC DISEASE AND 2017 UPDATE

08.30

Registration, introduction, authority welcome

P. Conte, F. Rea

09.00

∙ LECTURE ∙

Definition of oligometastatic NSCLC in the context of innovative treatments

P. Conte I SESSION

Diagnosis and staging of oligometastatic NSCLC

CHAIR PERSONS: S. Indraccolo, M. Saetta

10.00

The role of endoscopy in diagnosis and management of oligometastatic desease R. Trisolini

10.20

Immunomarkers for better

characterization of oligometastatic disease: role for diagnosis and treatment A.P. Dei Tos

10.40

Staging of oligometastatic lung cancer L. Evangelista

11.00 Discussion 11.15 Break

11.30

∙ LECTURE ∙

Indications, role and timing of surgical approach in oligometastatic NSCLC M. Alifano

II SESSION

Locoregional Treatments of oligometastatic NSCLC

12.00

∙ ROUND TABLE ∙

Locoregional approaches to oligometastases

SHOOTER: L. Bonanno

EXPERT PANELIST: M. Iacobone, F. Rea, U. Ricardi, P. Ruggieri, R. Stramare

12.50 Lunch III SESSION

Integrated management of oligometastatic NSCLC

CHAIRMAN: P. Conte

14.00

Medical management of oligoprogressive and/or slowly progressive disease

G. Scagliotti

14.30

Multidisciplinary Tumor Board:

Clinical Cases

1st case report

PRESENTER: M. Schiavon Panelist discussion

C. Aliberti, E. Bria, F. Calabrese, L. Ceron, A. Cervino, G. Pasello

2nd case report

PRESENTER: V. Polo

Panelist discussion

U. Fantoni, A. Favaretto, L. Loreggian, G. Marulli, R. Polverosi, A. Santo

15.30 Break

16.00

Padova University Thoracic Cancer Award 17.00

Adjourn, take home messages P. Conte, F. Rea

18.00

Cocktail reception THORACIC

ONCOLOGY PADOVA

09.00

∙ LECTURE ∙

Biological and therapeutic implication of tumor heterogeneity

G. Pelosi IV SESSION

Update on metastatic NSCLC

CHAIRMAN: P. Conte

09.30

Raising role of immunotherapy in NSCLC G. Scagliotti

10.00

New option for oncogene addicted NSCLCs: potential improvement in first line setting

A. Ardizzoni

10.30

New option for oncogene addicted NSCLCs: option for acquired resistance V. Gregorc

11.00 Discussion 11.10 Break V SESSION

Update on locally advanced disease

CHAIRMAN: F. Rea

11.30

Surgical approach U. Pastorino

12.00

Radiotherapy F. Alongi

12.30 Discussion 12.40

Take home messages, conclusion P. Conte, F. Rea

CAMILLO ALIBERTI Radiology, IOV, Padova MARCO ALIFANO

Thoracic Surgery, Hôpital Cochin, Paris FILIPPO ALONGI

Radiotherapy, Osp. Sacro Cuore Don Calabria, Negrar ANDREA ARDIZZONI

Medical Oncology, Università degli Studi di Bologna LAURA BONANNO

Medical Oncology2, IOV, Padova EMILIO BRIA

Medical Oncology, A.O.U. Integrata di Verona FIORELLA CALABRESE

Pathology, Università degli Studi di Padova LORIS CERON

Pneumology, ASL 12 , Mestre, Venezia ANNARITA CERVINO

Nuclear Medicine, IOV, Padova PIERFRANCO CONTE

Medical Oncology, Università degli Studi di Padova ANGELO PAOLO DEI TOS

Pathology, Azienda Ospedaliera di Treviso LAURA EVANGELISTA

Nuclear Medicine, IOV, Padova UMBERTO FANTONI

Pneumology, Università degli Studi di Padova ADOLFO FAVARETTO

Medical Oncology, Azienda Ospedaliera di Treviso VANESA GREGORC

Medical Oncology, Ospedale San Raffaele, Milano MAURIZIO IACOBONE

General Surgery, Università degli Studi di Padova STEFANO INDRACCOLO

Medical Oncology, IOV, Padova

DAY 1 • FRIDAY 31

st

, MARCH 2017

DAY 2 • SATURDAY 1

st

, APRIL 2017 FACULTY

LUCIO LOREGGIAN Radiation Oncology, IOV GIUSEPPE MARULLI

Thoracic Surgery, Università degli Studi di Padova GIULIA PASELLO

Medical Oncology 2, IOV, Padova UGO PASTORINO

Thoracic Surgery Istituto Nazionale Tumori Milano GIUSEPPE PELOSI

Pathology, Università degli Studi di Milano VALENTINA POLO

Medical Oncology 2, IOV, Padova ROBERTA POLVEROSI

Radiology, Azienda Ospedaliera San Donà di Piave FEDERICO REA

Thoracic Surgery, Università degli Studi di Padova UMBERTO RICARDI

Radiology, Università degli Studi di Torino PIETRO RUGGIERI

Orthopedy, Università degli Studi di Padova MARINA SAETTA

Pneumology Università degli Studi di Padova ANTONIO SANTO

Azienda Ospedaliera Universitaria Integrata di Verona GIORGIO SCAGLIOTTI

Medical Oncology, Università degli Studi di Torino MARCO SCHIAVON

Thoracic Surgery, Università degli Studi di Padova ROBERTO STRAMARE

Radiology, Università degli Studi di Padova ROCCO TRISOLINI

Pneumology, Università degli Studi di Bologna

Riferimenti

Documenti correlati

The meeting will be focused on colorectal liver metasta- ses treatments but specific sessions will be dedicated to neuroen- docrine and non-endocrine non-colorectal

LOCAL TREATMENTS IN CANCER THERAPY Chairs: Cinzia Iotti, Reggio Emilia, I. Claudio Pedrazzoli, Reggio Emilia, I Carlo Aschele, La Spezia, I Palliative liver surgery in mCRC

Tiseo 14.30-14.50 NSCLC fra terapie target e immunoterapia Stefano

Management of cardiovascular risk and hormonal deprivation in prostate cancer Il management del rischio cardiovascolare e della deprivazione ormonale nel cancro

L’approccio moderno al paziente con cancro polmonare, ed in particolare nella forma non-a piccole cellule (NSCLC), richiede una dimensione multidisciplinare con condivisione delle

11.00 stato dell’arte e prospettive di trattamento del nsclc alK e ros1

Surgical results and survival of older patients with unsuspected N2 stage IIIA non-small cell lung cancer.. The optimal treatment of N2 non-small cell lung cancer NSCLC in

Surgical results and survival of older patients with unsuspected N2 stage IIIA non-small cell lung cancer.. The optimal treatment of N2 non-small cell lung cancer NSCLC in